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Cryptococcus gattii, emergent on Vancouver Island,
British Columbia (BC), Canada, in 1999, was detected dur-
ing 2003–2005 in 3 persons and 8 animals that did not trav-
el to Vancouver Island during the incubation period;
positive environmental samples were detected in areas
outside Vancouver Island. All clinical and environmental
isolates found in BC were genotypically consistent with
Vancouver Island strains. In addition, local acquisition was
detected in 3 cats in Washington and 2 persons in Oregon.
The molecular profiles of Oregon isolates differed from
those found in BC and Washington. Although some micro-
climates of the Pacific Northwest are similar to those on
Vancouver Island, C. gattii concentrations in off-island envi-
ronments were typically lower, and human cases without
Vancouver Island contact have not continued to occur. This
suggests that C. gattii may not be permanently colonized in
off-island locations.
I
n 1999, Cryptococcus gattii emerged on Vancouver
Island, British Columbia (BC), Canada, among resi-
dents, visitors to the island, and domestic and wild animal
populations. Disease incidence on Vancouver Island
plateaued at 36 cases/million population/year during
2002–2005, markedly higher than rates reported in other
C. gattii–endemic areas (1,2).
Unlike the closely related species C. neoformans, a
common opportunistic pathogen of immunocompromised
hosts, C. gattii affects primarily immunocompetent per-
sons. Two C. gattii serotypes, B and C, have been
described (3). The fungus is acquired through inhalation of
airborne propagules and may cause pulmonary and central
nervous system disease. Activities that disturb colonized
soil or trees may increase the likelihood of exposure (4).
Disease acquisition likely also depends on host factors,
including underlying lung conditions and oral steroid use
(M. Fyfe, unpub. data).
In a study of Vancouver Island human C. gattii
serotype B cases from January 1999 through December
2001, infection was most common in men and those >60
years of age. Chest radiograph showed single or multiple
pulmonary nodules in 68% of patients. Symptoms includ-
ed severe cough and shortness of breath, often accompa-
nied by chills, night sweats, and anorexia. Approximately
20% of patients had cryptococcal meningitis (M. Fyfe,
unpub. data). The median incubation period was ≈6–7
months (5).
C. gattii has been isolated from more than 10 different
native tree species on Vancouver Island and from the sur-
rounding soil and air (6,7; S.E. Kidd et al., in press).
Despite sampling in areas both on and off the island, posi-
tive environmental isolates have, until recently, been con-
fined to the Coastal Douglas Fir and very dry Coastal
Western Hemlock biogeoclimatic zones along the east
coast of Vancouver Island (8, Figure 1).
VGIIa and VGIIb are the most commonly identified
genotypes among human, animal, and environmental iso-
lates from Vancouver Island (6). The VGI genotype has
been isolated less frequently from clinical and environ-
mental samples (6,9; S.E. Kidd et al., in press).
The emergence of C. gattii infection on Vancouver
Island, a temperate climate, was unusual because this
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notifiable in BC in 2003, formalizing laboratory reporting
originally developed in response to disease emergence. A
primary goal of surveillance was to monitor fungal spread
to other areas of BC.
Vancouver Island is the largest island on the Pacific
Coast of North America, covering 32,000 km2, with a pop-
ulation of ≈700,000. It is separated from the BC mainland
by the Strait of Georgia, a body of water ≈50 km wide that
contains several smaller islands known as the Gulf Islands
(Figure 1). Travel among Vancouver Island, the BC main-
land, and the Gulf Islands is very common, with an esti-
mated 17.3 million passengers transported on BC Ferries’
Vancouver Island routes annually (12).
Until 2004, all human cases of C. gattii infection
reported to the British Columbia Centre for Disease
Control were among those living on or traveling to
Vancouver Island during the year before symptoms
appeared. In December 2004, the first evidence of disease
in humans without exposure to Vancouver Island or other
known C. gattii–endemic areas was detected. This article
summarizes the epidemiologic and environmental support
for disease acquisition in parts of the BC lower mainland
and focal areas of the US Pacific Northwest.
Methods
Human Surveillance
We interviewed persons from whom C. gattii serotype
B was cultured through December 31, 2005, and who did
not report contact with Vancouver Island or other known
disease-endemic areas. We conducted telephone inter-
views by using a standard questionnaire to assess demo-
graphic information, travel history, risk factors for
infection, underlying medical conditions, and clinical
symptoms. Risk factors and travel exposures were
assessed for the 1-year period before the onset of illness
(or before diagnosis, in asymptomatic cases). Health
authorities in neighboring provinces (Canada) and states
(USA), where the disease is not reportable, were provided
with case investigation forms and encouraged to investi-
gate cryptococcal disease in immunocompetent persons.
Animal Surveillance
Reports of animal cases were informally collected
through veterinary networks in BC. Cases from the United
States were reported by state veterinary epidemiologists.
Infection in the animals was diagnosed histologically or
identified as C. gattii serotype B by culture. None of the
animals had traveled to Vancouver Island or other disease-
endemic areas. 
Environmental Surveillance
From October 2001 through December 2005, environ-
mental sampling was undertaken in the BC mainland, the
BC Gulf Islands, and the US Pacific Northwest. We sam-
pled 22 map grids as defined by the 1:50,000-scale
National Topographic System of Canada (NTS) and US
Geological Survey (USGS) mapping system. Geographic
data were assembled as described elsewhere (S.E. Kidd et
al., in press). Purposive sampling was conducted at select-
ed sites and areas surrounding the homes of persons with
C. gattii infection, those who reported travel to Vancouver
Island and those who did not. Sampled environments
included front and back yards, walking trails, public parks,
and recreational areas. Trees, small woody debris, soil, air,
and water were sampled as described elsewhere (S.E. Kidd
et al., in press). 
Sample positivity was scored binarily. C. gattii con-
centration was expressed as CFU/gram, CFU/m3, and CFU/
100 mL in soil, air, and water, respectively. The concentra-
tions of multiple samples were described by the geometric
mean and geometric standard deviation. When more than 1
sample was taken from a single sampling point (e.g., the
same tree), only the first sample was included.
Identification and Genetic Characterization
We initially cultured the samples on Staib media (13).
Resulting dark brown colonies were grown on canavanine-
glycine-bromothymol blue (CGB) agar (14) to differenti-
ate  C. gattii from  C. neoformans and then serotyped
(Crypto-check, Iatron Laboratories, Tokyo, Japan).
Molecular types were identified by a previously
described PCR-based restriction fragment length polymor-
phism (RFLP) method (15), which was adapted for further
discrimination of variation within the VGII molecular type
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Figure 1. Biogeoclimatic and geopolitical boundaries within British
Columbia.(9). The URA5 gene was amplified as previously described
(15) and then completely digested at 37°C in a 20-µLreac-
tion containing 1× NEB2 buffer, 1× bovine serum albumin,
and 4 U each of Hha I, Dde I, and BsrG I (New England
Biolabs, Inc., Ipswich, MA, USA). RFLP products were
subjected to electrophoresis and visualized on a 3%
agarose gel prestained with ethidium bromide. Control
strains were used for each possible C. gattii RFLP pattern:
WM179 (VGI), NIH444 (VGIIa), RB28 (VGIIb), WM161
(VGIII), and WM779 (VGIV). C. neoformans strains
WM148 (VNI), WM626 (VNII), WM628 (VNIII), and
WM629 (VNIV) were also included. 
Multilocus sequence typing was performed for select-
ed isolates by using methods previously described (8) with
the use of 2 additional loci, PLB1 and IGS (16). We isolat-
ed total DNA from histopathology specimens (n = 3) by
using the DNeasy Tissue kit (QIAGEN Inc., Mississauga,
Ontario, Canada). Cryptococcal-specific PCR-RFLP was
conducted as described above. The internal transcribed
spacer region (ITS1-5.8S-ITS2) was amplified and
sequenced for identification of C. gattii–specific polymor-
phisms (17).
Results
Epidemiology of Human Infection
Five persons with culture-confirmed C. gattii, 3 in BC
and 2 in Oregon, did not report exposure to Vancouver
Island or other cryptococcal disease–endemic areas
(Figure 2). Case-patients 1 through 4 received a diagnosis
or reported symptom onset from September through
December 2004. Case-patient 5, who had a fatal infection,
received a diagnosis in December 2005.
Case-patient 1 was a 47-year-old man living in BC
who was hospitalized with cough, chills, night sweats,
nausea, loss of appetite, muscle pain, headache, and neck
stiffness. Both lung and brain cryptococcomas were iden-
tified. He had chronic hepatitis C infection and a history of
drug addiction. At the time of infection, he smoked 20–40
cigarettes/day. His residence, a farmhouse undergoing sig-
nificant renovations, was located in NTS grid 092G/05 on
the coast north of Vancouver. Environmental exposures
included yard and landscaping work at this property.
Case-patient 2 was a 48-year-old woman living in BC
who experienced shortness of breath, fever, chills,
headache, night sweats, loss of appetite, nausea, and muscle
pain. Alung mass was identified by computed tomography.
She had no known underlying health conditions. She
resided on the BC lower mainland within NTS grid
092G/02; her last visit to Vancouver Island was 4 years
before the onset of her illness. In the year before onset, con-
siderable deforestation had occurred near her residence to
clear land for housing developments. During this period,
she also traveled ≈1 day/week to garden centers and nurs-
eries within NTS 092G/02 to obtain shrubs, trees, and new
topsoil for yard landscaping she carried out at her residence.
Case-patient 3 was a 73-year-old woman living in BC
who had chronic renal failure requiring dialysis and a his-
tory of lung disease and breast cancer. She was asympto-
matic; a cryptococcal lung nodule was identified
radiographically after she had hip surgery in December
2004. No nodule was apparent on imaging conducted <2
months earlier, which suggests recent acquisition. The
patient resided in NTS grid 092G/07. She last visited
Vancouver Island 14 years before her diagnosis. She had
reduced mobility and consequently little outdoor exposure.
Case-patient 4 was a 59-year-old man living in
Oregon who began to experience cough, shortness of
breath, fever, chills, weight loss, nausea, and muscle pain
in December 2004. He had undergone a kidney transplant
in September 2003 and reported scarring of lung tissue due
to his occupation. His place of residence was located with-
in USGS grid 44123-A1B4. He had not traveled outside
Oregon in the year before symptom onset.
Case-patient 5 was an 87-year-old man living in
Oregon (USGS grid 45122-C5D8). He was hospitalized in
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Figure 2. Location of human and animal Cryptococcus gattii cases
and positive environmental samples found off Vancouver Island.December 2005 with meningitis, accompanied by fever,
weight loss, and loss of appetite. His medical history
included chronic lymphocytic leukemia, and he had taken
oral steroids in the year before diagnosis. He had traveled
to parts of Oregon, Washington, and Colorado during his
exposure period.
Epidemiology of Off-island Animal Cases
In BC, a retrospective review of companion animal
cases identified 8 culture-confirmed serotype B cases,
which occurred in a ferret, a llama, and 6 cats. Specimens
were collected from December 2003 through December
31, 2005; animal residences were located throughout the
BC lower mainland (Figure 2).
In Washington, 3 cats with cryptococcal disease resid-
ing in USGS 48122-G1H4, close to the BC-USA border,
were reported from February through June 2005 (Figure
2). All cases were diagnosed by histopathologic examina-
tion, and no cultures were obtained.
Environmental Sampling
From October 2001 through December 2005, 3% of
2,033 off-island environmental samples were positive for
C. gattii (Table 1). Swab samples included 45% of sam-
ples from trees and other structures (n = 925), 38% from
soil (n = 781), 15% from air (n = 304), and 1% from water
(n = 23).
Five positive air samples were recovered from 2 focal
areas of the lower mainland at 2 different times (Figure 3).
The first 2 were collected from air in NTS grid 092G/02 on
the same day in October 2002. No other positive samples
were detected in 2003 despite further sampling at this site
and others. In July 2004, a third positive air sample was
collected from grid 092G/02 and 2 more from grid
092G/01. Despite extensive sampling in these areas and
other parts of the BC lower mainland (n = 1,140), C. gattii
was not isolated from colonized sources such as trees or
soil.
Among environmental samples taken outside
Vancouver Island, C. gattii was most often recovered from
the Gulf Islands (Table 1). NTS grid 092B/14 had the high-
est proportion of positive samples (52/220; 24%).
Colonized sources were identified from a single Gulf
Island within this grid in March, May, and June of 2004. In
2005, positive soil and tree samples were obtained in
February, August, September, and October from 3 of the
Gulf Islands (NTS grids 092B/14 and 092F/01) and
Washington (USGS grid 48122-G1H4). From among 50
samples collected a month apart in Washington within 10
km of the BC border (USGS grid 48122-G1H4), a single
soil sample and a swab of a fence post were positive. An
additional 27 samples from other sites along the US side of
the border (USGS grids 48122-G1H4 and 48122-G5H8)
were negative, as were all 197 samples collected from sev-
eral areas of Oregon (USGS grids 44123-A1B4 and
45122-C5D8). The geometric mean concentration of
detected C. gattii among soil and air samples taken from
Cryptococcus gattii in British Columbia and US Pacific Northwest
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Figure 3. Summary of non–Vancouver Island environmental sam-
pling effort, October 2001–December 2005. LM, lower mainland;
GI, Gulf Islands; WA, Washington.various sites outside Vancouver Island is summarized in
Table 2.
Molecular Typing Results for Human, Animal, 
and Environmental Isolates
Table 3 and Figure 4 summarize the molecular subtyp-
ing results for human and animal isolates from persons and
animals with no recent exposure to Vancouver Island, as
well as environmental isolates obtained from off-island
locations.
Of the 5 human cases, 3 were attributed to the VGIIa
molecular type, 1 to the VGIIb molecular type, and 1 to the
VGI molecular type. However, although all 3 molecular
types have been identified among clinical and environ-
mental isolates from Vancouver Island, multilocus
sequence typing (MLST) results indicated that both the
VGIIa and VGIIb strains from Oregon cases were geneti-
cally distinct from previously characterized Vancouver
Island isolates (9,16). The Oregon case 4 VGIIa isolate dif-
fered from Vancouver Island VGIIa at 1 locus, while
Oregon case 5 VGIIb differed from Vancouver Island iso-
lates at 4–5 loci, where it was more similar to Vancouver
Island VGIIa than VGIIb (Table 4).
Cryptococcal DNA isolated from the formalin-fixed,
paraffin-embedded tissue of 3 cats in Washington belonged
to the VGIIa molecular type. MLST profiles could not be
determined in these cases because of the relatively poor
quality and yield of DNA from the fixed tissue.
Most off-island environmental isolates that were
typed belonged to the VGIIa molecular type. These includ-
ed 4 of the 5 isolates from lower mainland air samples (the
fifth could not be separated from contaminants) and 90%
of 20 typed isolates from the NTS grid with the highest
proportion of positive off-island environmental samples
(092B/14). All tested environmental VGIIa isolates from
BC and Washington possessed identical MLST profiles to
those of representative isolates from Vancouver Island
(Table 3).
Discussion
Surveillance for C. gattii, conducted in BC since the
pathogen emerged on Vancouver Island, identified its
spread to off-island locations in 2005. To date, 3 humans
and 8 animals residing within the BC lower mainland who
had not traveled to Vancouver Island or other known cryp-
tococcal disease–endemic areas within the incubation peri-
od for disease have been found to have culture-confirmed
C. gattii infection. All but 1 case belonged to the VGIIa
subtype, the dominant genotype among clinical and envi-
ronmental isolates from Vancouver Island (6,9,16). Human
surveillance findings are supported by a parallel spread of
C. gattii to animal populations on the BC mainland and
positive air samples in this area. In addition, C. gattii
infections with no recent link to Vancouver Island or other
disease-endemic areas have been reported in 3 cats in
Washington and 2 persons in Oregon. These cases repre-
sent the first evidence of local disease acquisition in this
part of the United States. One historic case of VGIIa C.
gattii (NIH444) was diagnosed in Seattle in the early
1970s; however, residence and travel history for the infect-
ed person are unknown (6,9,16).
Before the identification of new disease–endemic
areas, all humans with C. gattii infection either lived with-
in or traveled to the Coastal Douglas Fir and very dry
Coastal Western Hemlock biogeoclimatic zones (Figure 1),
located along the eastern edge of Vancouver Island. These
zones are characterized by warm, dry summers and mild,
wet winters and extend into the southern Gulf Islands and
the BC lower mainland. Climates with comparable rainfall
and temperature extend south into parts of Washington and
Oregon in the United States (18). Franklin and Dyrness
(19) identified plant communities similar to those in BC in
the San Juan Islands and Puget Trough of Washington and
the Willamette Valley in Oregon. These ecologic likeness-
es to BC support the idea that C. gattii may colonize niche
areas of the US Pacific Northwest.
Although microclimate similarities exist, we could not
determine whether the isolation of C. gattii from areas
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transient dispersal of the organism at the time of sampling,
such as through wind flow or mechanical vectors/fomites.
Despite repeated sampling, no environmental source (e.g.,
tree, soil) of the VGIIa isolates detected in air on the BC
mainland has been found. Either an undiscovered reservoir
exists on the BC mainland or detectable airborne C. gattii
was aerosolized and dispersed from known colonized
sources, such as Vancouver Island or the Gulf Islands.
Washington VGIIa environmental isolates, identical by
MLST to those from BC, may represent recent dispersal
from BC or independent foci of colonization.
Sampling sites on Vancouver Island have shown dif-
ferent patterns of C. gattii colonization over time (4).
Transiently positive sites are characterized by a positive C.
gattii isolation, followed by a series of negative samples
over a period of months or years. Permanently colonized
sites consistently yield positive samples. Intermittently
colonized sites yield cycles of positive and negative sam-
ples over time, perhaps the result of population fluctuation
above and below the limits of detection as the organism
competes with local microbiota, while it adjusts to a new
ecologic niche. Repeated sampling of non–Vancouver
Island sites previously positive for C. gattii may show the
extent of colonization and the likelihood of these areas
becoming C. gattii–endemic.
The detected concentration of C. gattii in air and soil
samples from the BC lower mainland and northern
Washington was lower than in samples from Vancouver
Island. Based on a comparison of geometric means, the
detected C. gattii concentration in air samples from the
mainland was 4-fold lower than in Vancouver Island air
samples collected at the same time of the year (Table 2). C.
gattii concentration in soil from northern Washington and
2 of the Gulf Islands was ≈5× lower than in soil from
Vancouver Island. Only in a limited area of 1 particular
Cryptococcus gattii in British Columbia and US Pacific Northwest
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soil higher (3.3-fold) than in soil from Vancouver Island.
While direct comparisons with infected persons living
on or traveling to Vancouver Island are not possible
because of the small number of off-island cases, humans
affected by C. gattii in off-island environments may have a
higher rate of serious underlying health conditions. Among
cases in BC and Oregon, persons were affected by renal
failure, chronic hepatitis C infection, and cancer (i.e.,
chronic lymphocytic leukemia, breast cancer). In an age-
matched case-control study, persons from Vancouver Island
with C. gattii infection were not significantly more likely
than noninfected island residents to have had cancer (M.
Fyfe, unpub. data) or liver disease (L. MacDougall, unpub.
data). Persons with compromised immune systems may be
more susceptible to infection with C. gattii at the lower
concentrations observed in most off-island environments.
Even with ongoing surveillance in BC, the last report-
ed case of symptom onset in a person with C. gattii infec-
tion who had not traveled to Vancouver Island was in
December 2004. As of May 2006, no further cases had
been detected, a finding at odds with the notion of perma-
nent colonization. The onset of infections in the lower
mainland of BC (September–December 2004) coincides
with positive air samples on the mainland some months
earlier (July 2004), given known variations in individual
incubation periods (Figure 3) (5). Although animal cases
did continue to occur during 2005–2006, environmental
sampling attempts throughout 2005 did not detect the
organism in the lower mainland. This result indicates
either that permanent colonization did not occur in the
sampled areas or that C. gattii was present below the lim-
its of detection.
As on Vancouver Island, C. gattii in off-island areas
was first detected in companion animals. Animal cases
began to be regularly identified in March 2004, ≈6 months
before human illness was reported in this area. As on
Vancouver Island and in Australia, cats were affected more
often than other companion animals (20,21). However, ill-
ness occurred in a ferret and llama, rare animals also
infected early in the emergence on Vancouver Island,
which may suggest that these species are particularly sen-
sitive to infection. Despite substantial underreporting of
animal cases, data from Vancouver Island suggest that ani-
mal cases exceeded human cases by almost 75%, high-
lighting their value as a sentinel indicator of disease (20).
Clinical and environmental isolates from the BC
mainland, Gulf Islands, and northern Washington tested by
MLST were identical to representative isolates from
Vancouver Island at the 6 loci investigated (Table 4)
(9,16). However, although isolates from the C. gattii
human case-patients living in Oregon were typed as VGIIa
and VGIIb, MLST analyses indicated that these isolates
were genetically distinct from BC and Washington clinical
and environmental isolates. A BLAST comparison
(www.ncbi.nlm.gov/BLAST) to sequences from previous
studies and those represented in the National Center for
Biotechnology Information database identified Oregon
strains as genotypically unique (6,16). We have not identi-
fied an environmental source of C. gattii within Oregon or
any isolate possessing the same MLST profile as the
Oregon clinical strains. Oregon strains could represent an
independent population; alternatively, they may have
evolved from the VGIIa or VGIIb strains previously
described in BC or from VGIIa strains from California
(6,9,16), either through random genetic drift or through
sexual recombination. Recent studies suggest that same-
sex mating can occur among cryptococcal isolates and that
the VGIIa genotype may have arisen from same-sex mat-
ing between a strain of the VGIIb genotype and another
unknown strain (16,22).
Conclusion
C. gattii infections have been shown in human and
animal residents of the BC lower mainland and in
Washington and Oregon in the United States, despite no
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Figure 4. URA5-restriction fragment length polymorphism (RFLP)
profiles for selected human, animal, and environmental
Cryptococcus gattii isolates. A) URA5-RFLP to determine the
molecular type using Hha I and Sau96 I endonucleases (14).
B) URA5-RFLP to confirm molecular type and determine VGII
subtype, using Hha I, Dde I, and BsrG I endonucleases.contact with Vancouver Island or other known disease-
endemic areas. These findings may represent an expansion
of recognized areas where the disease is endemic.
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